Preclinical evaluation of drugs:
A) Biodistribution studies
The in vivo performance of drug delivery systems is directly conditioned by its biodistribution. Despite of this, the ability to perform in vivo biodistribution assays is usually limited by the capacity to track the molecules of interest. Our research team has an extensive experience in biodistribution studies by the labelling of therapeutic molecules and/or polymers with radioactive isotopes. The selection of different isotopes allows for the tracking of different molecules at the same time.
Abellan-Pose R, Rodríguez-Évora M, Vicente S, Csaba N, Évora C, Alonso MJ, Delgado A. Biodistribution of radiolabeled polyglutamic acid and PEG-polyglutamic acid nanocapsules. Eur J Pharm Biopharm. 2017;112:155-163.
Beloqui A, Solinís MÁ, Delgado A, Evora C, Isla A, Rodríguez-Gascón A. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J Microencapsul. 2014;31(1):1-8.
Beloqui A, Solinís MA, Delgado A, Evora C, del Pozo-Rodríguez A, Rodríguez-Gascón A. Biodistribution of Nanostructured Lipid Carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm. 2013;84(2):309-14.
B) In vivo release kinetics
Besides the conventional in vitro release studies and mass transfer coefficients assessment the DDSys group has also a broad background performing in vivo release kinetics analysis. These studies allow to correlate in vitro-in vivo data crucial for the translation of the pharmaceutical formulations/therapeutic molecules to the clinic.
Pérez-Herrero E, García-García P, Gómez-Morales J, Llabrés M, Delgado A, Évora C. New injectable two-step forming hydrogel for delivery of bioactive substances in tissue regeneration. Regen Biomater. 2019;6(3):149-162.
Segredo-Morales E, Reyes R, Arnau MR, Delgado A, Évora C. In situ gel-forming system for dual BMP-2 and 17β-estradiol controlled release for bone regeneration in osteoporotic rats. Drug Deliv Transl Res. 2018;8(5):1103-1113.